NCT03518242View on ClinicalTrials.gov

Molecular Profile of Breast Cancer in Ugandan Patients With Stage IIB-III Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

June 6, 2018

Primary Completion Date

May 4, 2022

Study Completion Date

May 4, 2022

Conditions
Breast Cancer FemaleAnatomic Stage IIB Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Invasive Breast CarcinomaPrognostic Stage IIB Breast Cancer AJCC v8Prognostic Stage III Breast Cancer AJCC v8Prognostic Stage IIIA Breast Cancer AJCC v8Prognostic Stage IIIB Breast Cancer AJCC v8Prognostic Stage IIIC Breast Cancer AJCC v8
Interventions
DRUG

Cyclophosphamide

Given PO

DRUG

Methotrexate

Given PO

DRUG

Capecitabine

Given PO

PROCEDURE

Biospecimen Collection

Undergo biospecimen collection

Trial Locations (2)

256

New Mulago Hospital, Kampala

3935

Uganda Cancer Institute, Kampala

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Fred Hutchinson Cancer Center

OTHER